Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Biotech industry downturn: Struggles continue as layoffs mount and funding dwindles

By Brian Buntz | March 29, 2023

Layoffs due to financial crisis, coronavirus vector concept. Symbol of job losses, downsizing, firing people. Depression, recession in markets and corporate world. Minimal art style Eps10 illustration

[jozefmicic/Adobe Stock]

The once-thriving biotech industry, known for breakthroughs in cell therapy, gene editing, and messenger RNA, is now showing signs of a downturn. During the early days of the pandemic, mRNA vaccine trailblazers like Moderna (Nasdaq:MRNA), Pfizer (NYSE:PFE), and BioNTech (Nasdaq:BNTX) enjoyed skyrocketing revenues, but the recent biotech industry downturn has cast a shadow over this previous success.

Layoffs and shrinking stock offerings: Biotech downturn takes its toll

But in recent months, biotechs have laid off thousands of employees, stock offerings have decreased and notable biotech stocks have plunged, although the Nasdaq Biotechnology Index (Index) is up about 2% so far in 2023. Conversely, the iShares Biotechnology exchange-traded fund (an equal-weighted index of biotech stocks) has fallen about 4.5%.

As biotech companies struggle to raise capital and stay in business, industry analysts like Michael Yee from Jefferies, as mentioned in a February WSJ article, predict a growing divide between the “haves” and “have-nots.”

Biotech companies experienced significant layoffs in 2022, with more than 7,000 people losing their jobs. In January 2023 alone, the sector reported 1,449 layoffs, according to WSJ. By contrast, there were 174 in the same month a year earlier. So far this year, 19 biotech firms have announced workforce reductions. Many pharma companies have done the same. This trend of layoffs and company closures marks a substantial shift for the biotech industry, which previously has proven resilient at fundraising.

Factors contributing to the biotech industry downturn

  1. Rising interest rates: As investors seek safer ways to make money amid rising interest rates, the biotech industry’s ability to attract funding has diminished. Some analysts, however, note that the impact of rising interest rates has been relatively modest.
  2. Difficulty in developing profitable products: Some initially promising technologies, such as cell and gene therapies, have proven challenging to develop into profitable products.
  3. Political tensions between the U.S. and China: Uncertainty resulting from political tensions has affected the industry’s outsourcing of manufacturing and drug development, leading to increased concerns over supply chain disruptions and potential delays in drug production. Meanwhile, Chinese biotech companies are thriving, as Reuters noted.
  4. The Inflation Reduction Act, a new federal law allowing Medicare to negotiate drug prices: The uncertainty surrounding the extent of potential discounts has added to the industry’s concerns.

Not all doom and gloom? Some biotechs still thriving

Despite the biotech industry downturn, some biotech companies continue to fare well, with investors upbeat about promising drugs for obesity, psoriasis and liver disease. The new Alzheimer’s drug Leqembi (lecanemab) from Eisai (OTCMKTS:ESALY) and Biogen (Nasdaq:BIIB) has also raised hopes that the industry is making progress in tackling the disease. Several biotechs have accumulated significant cash reserves, enabling them to make acquisitions, and some pharmaceutical companies are actively seeking deals, as WSJ has noted,

Fundraising challenges

Biotechs raised $1.57 billion through IPOs in 2022, a significant decrease from the $16.5 billion raised in 2021, according to WSJ The traditional path of raising money through venture capital and institutional investors, followed by going public, has become more challenging. Venture capitalists are now more cautious about investing in mid- or later-stage privately-held biotechs.

Examples of struggling companies include the following:

  1. Finch Therapeutics Group Inc. halted the development of its most advanced drug, sold its other assets, and laid off 95% of its staff.
  2. Goldfinch Bio Inc. shut down after failing to raise money.
  3. Vyant Bio Inc. is seeking strategic alternatives.
  4. Cyteir Therapeutics Inc. laid off 70% of its workforce and halted the development of all drugs except for its lead product for ovarian cancer treatment.
  5. Magenta Therapeutics Inc. halted its drug pipeline development and is considering options, including a sale or merger.
  6. Rubius Therapeutics Inc. reduced its workforce by 82%.

The biotech industry downturn has accelerated recently, with thousands of employees getting the boot, funding drying up and companies struggling to keep their heads above water. It’s a perfect storm of rising interest rates, product development hiccups, political tensions and onerous new laws that have thrown the industry for a loop. But there are still some biotech high-flyers grabbing investor attention and pushing the envelope in biotech drug development. The industry will need to buckle up, think outside the box and tap into new funding wellsprings and strategies to ride out these challenges and steer a course towards growth and sustainability.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

This is the logo of BD.
BD lays off 100 at biotech reagent plant in California
This is the logo of Bayer.
Bayer plans significant job cuts as it restructures
This is the logo of Pfizer.
Pfizer restructuring push hits Ireland
Multi Color DNA Structure On Black Backdrop Generative AI
Forecast 2024: Pharma industry grapples with regulatory hurdles and AI opportunities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE